Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XBIO | US
0
0%
Healthcare
Biotechnology
30/06/2024
08/06/2026
3.09
3.11
3.17
3.09
Xenetic Biosciences Inc. a biopharmaceutical company focuses on advancing XCART a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition the company leveraging PolyXen its proprietary drug delivery platform by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd. Serum Institute of India Limited and PJSC Pharmsynthez. Xenetic Biosciences Inc. is headquartered in Framingham Massachusetts.
View LessValue Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
63.3%1 month
56.5%3 months
77.6%6 months
74.6%-
-
0.79
-
-
1.03
0.12
-
-5.75M
4.77M
4.77M
-
-184.11
-
11.60
-48.61
0.20
0.21
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.57
Range1M
0.74
Range3M
1.48
Rel. volume
0.43
Price X volume
18.87K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.16 | 5.19M | 4.50% | n/a | 0.00% |
| Pulmatrix Inc | PULM | Biotechnology | 1.42 | 5.19M | 6.77% | n/a | 0.18% |
| Biofrontera Inc. Common Stock | BFRI | Drug Manufacturers-Specialty & Generic | 0.93 | 5.16M | -0.53% | n/a | 13.20% |
| Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 4.21 | 4.98M | -5.18% | n/a | 0.22% |
| NuCana plc | NCNA | Biotechnology | 2.05 | 4.61M | 5.13% | n/a | 0.00% |
| Purple Biotech Ltd | PPBT | Biotechnology | 2.92 | 4.60M | -1.68% | n/a | 0.89% |
| SNTI | SNTI | Biotechnology | 0.9416 | 4.31M | -2.47% | n/a | 80.96% |
| Brainstorm Cell Therapeutics Inc | BCLI | Biotechnology | 0.8 | 4.25M | n/a | -27.28% | |
| CollPlant Holdings Ltd | CLGN | Biotechnology | 0.37 | 4.24M | -0.27% | n/a | 0.00% |
| Matinas BioPharma Holdings Inc | MTNB | Biotechnology | 0.82 | 4.11M | 3.93% | n/a | 16.97% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.03 | 0.53 | Expensive |
| Ent. to Revenue | 0.12 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.79 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 77.57 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 4.77M | 3.66B | Emerging |